Sign In
Buy NVAX
$10.20
-0.0100 (-0.0979%)
At Close: Jun 03, 2026
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
10:01am, Monday, 08'th Dec 2025
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dow Jones Today: Stock Indexes Close Lower to Begin December Trading; Big Tech, Crypto-Tied Shares Drop Amid Risk-Off Sentiment
08:00pm, Monday, 01'st Dec 2025
Major stock indexes pulled back as the final trading month of the year began, with shares of big tech and cryptocurrency-tied firms falling amid risk-off sentiment.
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
03:50pm, Monday, 01'st Dec 2025
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
12:35pm, Monday, 01'st Dec 2025
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
09:59am, Monday, 01'st Dec 2025
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
10:01am, Tuesday, 25'th Nov 2025
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript
02:33pm, Wednesday, 19'th Nov 2025
Novavax, Inc. ( NVAX ) Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM EST Company Participants Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kel
Shah Capital pushes for Novavax sale, warns of proxy fight
04:41pm, Wednesday, 12'th Nov 2025
Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is
Novavax to Participate in Jefferies London Healthcare Conference
08:00am, Wednesday, 12'th Nov 2025
GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Jefferies London Healthcare Conf
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
10:01am, Tuesday, 11'th Nov 2025
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
12:31pm, Friday, 07'th Nov 2025
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript
03:26pm, Thursday, 06'th Nov 2025
Novavax, Inc. ( NVAX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Devel
Novavax (NVAX) Reports Q3 Loss, Beats Revenue Estimates
10:16am, Thursday, 06'th Nov 2025
Novavax (NVAX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to a loss of $0.76 per share a year ago.
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
08:00am, Thursday, 06'th Nov 2025
Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on mar
Novavax raises annual revenue forecast on strength of vaccine deals
07:58am, Thursday, 06'th Nov 2025
Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.
